Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.3%

Eli Lilly and Company (NYSE:LLY) rose 0.3% during trading on Tuesday . The company traded as high as $956.39 and last traded at $953.74. Approximately 435,166 shares changed hands during trading, a decline of 85% from the average daily volume of 2,909,118 shares. The stock had previously closed at $950.46.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $1,001.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, Barclays raised their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $858.72.

Eli Lilly and Company Trading Down 6.3 %

The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a 50-day simple moving average of $859.02 and a 200 day simple moving average of $771.34. The company has a market capitalization of $806.80 billion, a P/E ratio of 126.05, a P/E/G ratio of 2.06 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the firm earned $1.62 EPS. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 13.71 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total value of $1,318,543.82. Following the completion of the sale, the insider now directly owns 97,367,369 shares in the company, valued at approximately $89,093,089,982.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the business. Lynx Investment Advisory acquired a new position in Eli Lilly and Company in the second quarter worth $32,000. Lipe & Dalton acquired a new position in Eli Lilly and Company in the fourth quarter worth $26,000. Core Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Activest Wealth Management acquired a new position in Eli Lilly and Company in the first quarter worth $39,000. Finally, Tidemark LLC acquired a new position in Eli Lilly and Company in the fourth quarter worth $29,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.